Table 6. .
Expression of RPS19 mRNA Normalized to GAPDH in Lymphoblastoid Cell Lines in Diseased and Control Samples[Note]
| Sample Group and Sample ID(s) |
RPS19 Average CT | GAPDH Average CT | ΔCT RPS19 − GAPDH | ΔΔCT (ΔCT−ΔCT,C) |
RPS19 Normalized to GAPDH (2-ΔΔCT) |
| Controls: | |||||
| C1–C4 | 18.00 ± .56 | 16.46 ± .48 | 1.78 ± .74 | .00 ± 1.04 | 1.0 (.49–2.06) |
| RPS24-mutated samples: | |||||
| D1 | 18.30 ± .10 | 17.82 ± .13 | .48 ± .17 | −1.30 ± .76 | 2.46 (1.46–4.15) |
| D2 | 17.79 ± .16 | 17.49 ± .23 | .30 ± .28 | −1.48 ± .79 | 2.78 (1.61–4.81) |
| D3 | 17.81 ± .32 | 16.49 ± .30 | 1.47 ± .44 | −.31 ± .86 | 1.24 (.68–2.24) |
| RPS19-mutated samples: | |||||
| D4 | 17.60 ± .14 | 16.70 ± .05 | .90 ± .14 | −.87 ± .75 | 1.83 (1.09–3.09) |
| D5 | 19.25 ± .05 | 18.20 ± .05 | 1.06 ± .07 | −.72 ± .74 | 1.65 (.99–2.76) |
| D6 | 19.43 ± .21 | 16.64 ± .21 | 2.78 ± .30 | 1.01 ± .80 | .50 (.29–.87) |
| Non–RPS19/RPS24-mutated samples: | |||||
| D7 | 19.04 ± .31 | 17.33 ± .08 | 1.71 ± .32 | −.07 ± .80 | 1.05 (.60–1.83) |
| D8 | 19.15 ± .28 | 19.11 ± .11 | .04 ± .30 | −1.74 ± .80 | 3.33 (1.92–5.78) |
| D9 | 17.68 ± .47 | 16.61 ± .18 | 1.07 ± .51 | −.71 ± .89 | 1.63 (.88–3.04) |
| D10 | 17.46 ± .20 | 17.28 ± .24 | .18 ± .31 | −1.60 ± .80 | 3.03 (1.74–5.28) |
Note.— C1–C4 are control samples, and D1–D10 are diseased samples. CT = number of cycles; CT,C = number of control cycles.